Prestige Consumer Healthcare (PBH) reported $265.71 million in revenue for the quarter ended June 2026, representing a year-over-year increase of 6.5%. EPS of $0.98 for the same period compares to $0.95 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $250.25 million, representing a surprise of +6.18%. The company delivered an EPS surprise of +10.11%, with the consensus EPS estimate being $0.89.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Prestige Consumer Healthcare performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenues- OTC Healthcare- International: $39.5 million compared to the $36.73 million average estimate based on three analysts. The reported number represents a change of +6.9% year over year. Revenues- OTC Healthcare- North American: $226.21 million versus the three-analyst average estimate of $213.64 million. The reported number represents a year-over-year change of +6.4%. Gross profit- OTC Healthcare- North American: $115.94 million versus $118.14 million estimated by two analysts on average. Gross profit- OTC Healthcare- International: $20.25 million versus $19.57 million estimated by two analysts on average.View all Key Company Metrics for Prestige Consumer Healthcare here>>>
Shares of Prestige Consumer Healthcare have returned +9.7% over the past month versus the Zacks S&P 500 composite's +3.3% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention.
See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Prestige Consumer Healthcare Inc. (PBH): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).